Slide 1: NRXS
NRXS June 2026 NYSEAMERICAN: NRXS | NeurAxis.com
Slide 2: Forward Looking Statements
2 | Forward Looking Statements Information included herein has been prepared by NeurAxis, Inc. (“NeurAxis”) or obtained from These forward-looking statements are subject to a number of risks, uncertainties and sources believed to be reliable, but the accuracy or completeness of such information is n
Slide 3: Who We Are
3 | Who We Are Neuromodulation Therapies for Chronic and Debilitating GI Conditions in Pediatrics and Adults NeurAxis is a First-to-Market growth-stage Medtech company focused on neuromodulation therapies for chronic and debilitating conditions in GI, specifically from disorders of gut-brain interac
Slide 4: Corporate Overview
4 | Corporate Overview Secured a Category I CPT® code for the PENFS technology, obtained significant expanded commercial payer coverage and have the only FDA- approved or FDA-cleared treatment recommended in the Guidelines. Category I CPT Code – PENFS Med Policy Coverage Streamlined Billing & RVUs >
Slide 5: FDA Pipeline - Indications and Timelines
FDA Pipeline - Indications and Timelines 5 | Indication 2023 2024 2025E 2026E 2027E Clinical Study* Functional Abdominal Pain & IBS- - Children's Wisconsin RCT** -Pediatric Functional Dyspepsia (Nausea) RCT/Registry - Pediatric Functional Dyspepsia (Nausea) -Adult Device Extrapolation Functional Dys
Slide 6: Strong Policy Coverage & Reimbursement = Strong Revenue Growth
6 | NeurAxis PENFS1: First FDA Indicated Treatment for Pediatric FAP/IBS 2 Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth Large Global Market with Significant Unmet Need Unique, Innovative Product ▪ $ 22B+ SAM3 for target pipeline indications Supported by Clinical Evide
Slide 7: $22B+ Serviceable Available U.S. Market (SAM) for Pipeline Indications
7 | $22B+ Serviceable Available U.S. Market (SAM) for Pipeline Indications Pediatric Indications Adult Indications $2B $1B CVS $2B Concussion RED $8B $2B Functional $14B Pediatric SAM* Dyspepsia SAM* $12B FAP/IBS $3B FAP/IBS Why Pediatrics? Entering Pediatric markets first with: ▪ Significant unmet
Slide 8: Abnormal processing of signals to and from the gut
8 | Abnormal processing of signals to and from the gut Disorders of the Gut-Brain Interaction (DGBIs) Irritable Bowel Cyclic Vomiting Syndrome Functional Recurrent episodes of intense Syndrome (IBS) Dyspepsia nausea and vomiting lasting Characterized by abdominal Pain or discomfort hours to days wit
Slide 9: DGBIs: A Problem with an Unmet Need
9 | DGBIs: A Problem with an Unmet Need ▪ No FDA-approved therapies for children with abdominal pain-related disorders of the gut-brain interactions (DGBIs). ▪ Disorders negatively impact quality of life and ability to function (attend school, sports, and social activities). ▪ Insufficient data to s
Slide 10: Established Technology with Demonstrated Safety and Efficacy
10 | Established Technology with Demonstrated Safety and Efficacy What is IB-Stim? ▪ PENFS system intended for patients 8 years of age and older with functional abdominal pain (FAP) associated with IBS FDA De Novo & Expanded 510K ▪ Aids in pain reduction via neuromodulation to clearance branches of
Slide 11: IB-Stim Research: By the Numbers
11 | IB-Stim Research: By the Numbers Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth 21 PENFS Technology and NRXS Related Studies 13 Children’s Hospital Study Sites 10 Types of Studies ▪ Double Blind Placebo Controlled ▪ Real World Clinical Data ▪ Long-Term Data ▪ Pre-c
Slide 12: Percutaneous Electrical Nerve Field Stimulation (PENFS)
12 | Percutaneous Electrical Nerve Field Stimulation (PENFS) How Does Neuromodulation Work? * Access Stimulate Change 1 Direct access to central nervous system (CNS) through 2 Stimulation reduces firing of amygdala 3 Induces changes in brain pathways/connectivity peripheral cranial nerves * Second G
Slide 13: Data Does Not Support Standard Pharmacotherapy in Children with IBS
13 | Data Does Not Support Standard Pharmacotherapy in Children with IBS No data to support use Significant Risk of TCA Substantial Patient of Antidepressants in Side Effects in Children Need for Safe & Effective, Children with Functional Non-Pharmacological ▪ Increased risk of suicidal Abdominal Pa
Slide 14: Growing Body of Clinical Evidence
14 | Growing Body of Clinical Evidence Improvement of Global Symptoms in Patients with Irritable Bowel Syndrome Global Symptom Improvement *Percent of patients reporting improvement of global symptoms using Symptom Response Scale score ≥2 (*p≤0.001), ≥3 (#p=0.002) and ≥4 (p=0.077) Kovacic K, et al.
Slide 15: FDA Benchmark for Clinically Meaningful Endpoint
15 | FDA Benchmark for Clinically Meaningful Endpoint Treatment for abdominal pain-related functional ≥30% Improvement in Pain gastrointestinal disorders in adolescents: ▪ Number Needed to Treat (NNT): The number of patients that need to be treated for one patient to get the targeted improvement (≥3
Slide 16: Functional Disability Scores at Long-Term Follow-Up
16 | Functional Disability Scores at Long-Term Follow-Up Improvement in Functional Disability in Patients with Irritable Bowel Syndrome Improving functional disability (attending school and activities) is a marker of overall health and clinically meaningful beyond subjective pain measures. Kovacic K
Slide 17: Largest Pediatric Registry in Children with DGBI
17 | Largest Pediatric Registry in Children with DGBI ▪ Pediatric registry with “real world” clinical data ▪ 61% had failed ≥ 4 medications prior to treatment ▪ Sustained efficacy in abdominal pain up to 6-12 months after 4 weeks if IB-Stim treatment A multicenter registry study on percutaneous elec
Slide 18: IB-Stim was equivalent or better than standard medications used for FAPDs
18 | IB-Stim was equivalent or better than standard medications used for FAPDs Confidential – Do Not Distribute
Slide 19: IB-Stim Go-to-Market Strategy
19 | IB-Stim Go-to-Market Strategy Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth 2026 Med Policy Coverage Reimbursement Strategy Total Total # Lives Technology Specific CPT Coding Plans Covered CAT I CPT code Effective 1/1/26 >26 >101M List Price $1,195 Customers Child
Slide 20: NeurAxis IP Portfolio
20 | NeurAxis IP Portfolio ▪ 13 issued and 9 pending patents ▪ Device ▪ Method ▪ U.S. IP runs through 2039 as of now ▪ International IP in process ▪ Freedom to operate completed Confidential – Do Not Distribute
Slide 21: Collaborative Contract Manufacturing Partner
21 | Collaborative Contract Manufacturing Partner In-House Capabilities Manufacturing Capacity Quality Management System ▪ Office and factory in Indiana ▪ Controlled, repeatable, monitored ▪ ISO 13485:2016 Certified ▪ 69,000 square foot facility production process ▪ FDA registered ▪ Offices, factory
Slide 22: Medical Advisory Board
22 | Medical Advisory Board Dr. Samuel Nurko Dr. Carlo Di Lorenzo Dr. Rachel Rosen Dr. Kahlil El-Chammas Dr. Miranda van Tilburg Dr. Leonel Rodriguez Confidential – Do Not Distribute
Slide 23: Management Team
23 | Management Team Brian Carrico Dr. Adrian Miranda Timothy Henrichs Dr. Tom Carrico Dr. Chris Brown Chief Executive Officer, Chief Medical Officer Chief Financial Officer Chief Regulatory Officer Director Of Innovation, Board Member Founder, Board Member Confidential – Do Not Distribute
Slide 24: Board of Directors
24 | Board of Directors Beth Keyser Mitch Watkins Kirstin Ferge Brian Carrico Dr. Chris Brown Dr. Gil Aharon Board Member Board Member Board Member Chief Executive Officer, Director Of Innovation, Board Member Board Member Founder, Board Member Collective Experience: Confidential – Do Not Distribute
Slide 25: Key Investment Highlights
25 | Key Investment Highlights Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth Large Global Market with Significant Unmet Need Unique, Innovative Product ▪ $22B+ SAM 1 for target pipeline indications Supported by Clinical Evidence ▪ $8B+ SAM1 for target pediatric indicat
Slide 26: Expanding Portfolio of Next Generation Devices for Disorders of Gut-Brain Interaction
26 | Expanding Portfolio of Next Generation Devices for Disorders of Gut-Brain Interaction RED – Rectal Expulsion Device ▪ Developed at the University of Michigan Compressed enabling comprehensive constipation care for every adult gastroenterology practice Red Device ▪ RED is a self-inflating balloo
Slide 27: Capital Structure
27 | Capital Structure Stock Information Listing NYSE Symbol NRXS Share Price (May 22, 2026) $7.38 Share Structure (May 2026) Shares Outstanding 12.4 M Warrants 1.1 M Options/RSUs 2.6 M Series B Preferred 3.7 M Shares fully diluted 19.8 M Financial Position (May 2026) Cash Position $7.1 M Long-term
Slide 28: Contact Information
28 | Contact Information Investor Relations Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com Confidential – Do Not Distribute
Slide 29: Thank you
Thank you NYSEAMERICAN: NRXS | NeurAxis.com